Study of Comparative Treatments for Retinal Vein Occlusion 2 (SCORE2)
Status:
Completed
Trial end date:
2021-03-01
Target enrollment:
Participant gender:
Summary
SCORE2 is a multicenter, prospective, randomized, phase III clinical trial in which all
participants enrolled will be followed for up to 2.5 years. SCORE2 is designed as a
non-inferiority trial, with study eyes randomized to intravitreal bevacizumab (1.25 mg) every
4 weeks vs. intravitreal aflibercept (2.0 mg) every 4 weeks. SCORE2 aims to determine if
bevacizumab is non-inferior to aflibercept for the treatment of macular edema associated with
central retinal vein occlusion (CRVO), with the primary outcome of visual acuity measured at
Month 6.
Phase:
Phase 3
Details
Lead Sponsor:
The Emmes Company, LLC The EMMES Corporation
Collaborators:
Milton S. Hershey Medical Center National Eye Institute (NEI) University of Wisconsin, Madison